T-knife Therapeutics

t-knife therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, initially focused on t cell receptor (tcr) engineered t cell therapies (tcr-ts), a modality that holds the potential to generate transformative responses in patients with solid tumors. the company’s unique approach leverages its proprietary hutcr mouse platform, a next-generation t cell receptor and epitope discovery engine that produces fully human, tumor-specific tcrs, naturally selected in vivo for optimal affinity and high specificity. t-knife is advancing a portfolio of tcr-t product candidates against targets with high unmet medical need, including cancer testis antigens, oncoviral antigens and commonly shared tumor-driving neoantigens. t-knife was founded by leading t-cell and immunology experts using technology developed at the max delbruck center for molecular medicine together with charité – universitätsmedizin berlin.